Key information
Since 2020, CVC Credit has supported the development of Curium, the world’s leading provider of nuclear medicine. Over this period, the company has delivered strong organic growth and completed multiple acquisitions. Its recent recapitalisation, which included CVC Credit Capital Solutions, represented the largest transaction ever completed in the nuclear medicine sector.
Region
Sector
Strategy
Helping save lives around the world
Founded in 2017 through the combination of two nuclear imaging businesses, Curium manufactures and distributes products used in diagnostic imaging, including the early detection of cancer as well as heart, brain, lung, and bone diseases. The company also has a promising pipeline of therapeutic products for the treatment of cancer.
In November 2025, Curium and CapVest announced the recapitalisation of the company through a new Continuation Vehicle. With deep knowledge of the business from CVC Private Equity and CVC Secondaries, combined with CVC Credit’s position as a lender to Curium for more than five years, CVC Credit was able to leverage this experience to move quickly and secure the transaction.
The recapitalisation valued the business at approximately $7bn and is expected to further strengthen Curium’s strategy to launch lifechanging diagnostic and therapeutic solutions for cancer patients worldwide.
Such strong investor interest endorses our position as the largest independent platform in nuclear medicine. Our recent recapitalisation positions us to accelerate our ambitious global strategy, and drive product launches, innovation and growth – changing the lives of millions of patients.
Renaud Dehareng CEO, Curium